CHAMPION HF Risk Algorithm (Prototype)

Clinical calculation support · Verify results before clinical use

Patient parameters

Complete all required fields. NT-proBNP is optional.

— Points
Prototype assigns 1 point at age ≥75 years.
Class II = 0, III = 2, IV = 3 prototype points.
Prototype scoring thresholds: ≥25 and <35 mmHg, or ≥35 mmHg.
Prototype assigns 1 point when LVEF is <40%.
Prototype thresholds: ≥1.5 and ≥2.0 mg/dL.
Leave blank if unavailable. Prototype thresholds: ≥1000 and ≥2000 pg/mL.
Reset

About this prototype

This educational tool assigns heuristic points to selected clinical variables: age, NYHA class, recent HF hospitalization, mean pulmonary artery pressure, LVEF, serum creatinine, and optional NT-proBNP. The weights and category boundaries are retained from the supplied source file and have not been clinically validated.

Scoring rules implemented

VariablePrototype rulePoints
Age≥75 years+1
NYHA classIII / IV+2 / +3
Prior HF hospitalizationWithin 12 months: yes+3
mPAP25–<35 / ≥35 mmHg+2 / +4
LVEF<40%+1
Creatinine≥1.5–<2.0 / ≥2.0 mg/dL+1 / +2
NT-proBNP (optional)≥1000–<2000 / ≥2000 pg/mL+1 / +2

Prototype category boundaries

Total pointsPrototype category
0–2Low
3–5Moderate
6–8High
≥9Very high

Clinical context and evidence

The CHAMPION trial studied pulmonary artery pressure-guided management using the CardioMEMS system in patients with chronic heart failure. Its published results support the study of pressure-guided management, but they do not validate the heuristic point weights or risk categories implemented in this page.

The mPAP thresholds used for points here are prototype-specific. Contemporary ESC/ERS guidance defines pulmonary hypertension haemodynamically as mPAP >20 mmHg at rest, assessed by right heart catheterization; mPAP alone does not establish the full haemodynamic phenotype. The prototype thresholds must not be interpreted as diagnostic cutoffs.

Abraham WT, Stevenson LW, Bourge RC, et al.Sustained efficacy of pulmonary artery pressure to guide adjustment of chronic heart failure therapy: complete follow-up results from the CHAMPION randomised trial. The Lancet. 2016;387(10017):453–461. DOI: 10.1016/S0140-6736(15)00723-0. PMID: 26560249.
Humbert M, Kovacs G, Hoeper MM, et al.2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. European Heart Journal. 2022;43(38):3618–3731. DOI: 10.1093/eurheartj/ehac237.